OBJECTIVE: We conducted this population-based study to detect the prevalence and
associated factors of diabetes in patients with major depressive disorder (MDD) in Taiwan …

Depression remains a highly prevalent and mostly recurrent disorder causing an increased
need to optimize and broaden the current therapy options. An enormous body of evidence …

Background: Patients with major depressive disorder (MDD) who fail to achieve complete
remission with antidepressant therapy may benefit from augmentation therapy with an …

To examine the efficacy and overall tolerability of the simultaneous initiation of treatment
(coinitiation) with triiodothyronine (T3) and a selective serotonin reuptake inhibitor (SSRI) for …

Background: Major depressive disorder is a psychiatric disorder that affects 4.4% of the
population worldwide. Although the majority of antidepressant drugs ameliorate depressive …

OBJECTIVE: To determine whether the combination of triiodothyronine (T3) plus sertraline at
treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in …

Objective: To compare 2 methods of switching selective serotonin reuptake inhibitor (SSRI)
nonresponders or partial responders to duloxetine. Method: Adult outpatients with DSM-IV …

Depression is one of the leading causes of mental disability worldwide and a significant
public health problem in the United States. Individuals with depression have lower quality of …

The article discusses the use of antidepressant combination therapies for the treatment of
major depression. A growing trend in psychopharmacology is combining two drugs from the …

The objective of this study was to investigate whether quetiapine, when compared with
placebo, can speed the onset of action and improve the quality of response to fluoxetine …